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Background/Aims: Chronic hepatitis C virus (HCV) 
infection is associated with a higher risk of the devel-
opment of insulin resistance. If HCV is a causal factor 
for insulin resistance, then clearance of HCV might 
decrease insulin resistance. The aim of this study was 
to elucidate the effects of clearance of HCV on in-
sulin resistance. Methods:  We analyzed 28 patients 
with HCV infection who received combination treat-
ment of 180 μg of pegylated interferon α-2a and rib-
avirin at our institution from May 2004 to November 
2006. Insulin resistance was calculated according to 
the homeostasis model assessment of insulin resist-
ance (HOMA-IR) method. Results:  Twenty-two patients 
(78.6%) achieved sustained virologic response (SVR), 
where the fasting plasma glucose level significantly 
decreased after antiviral treatment. Fasting serum in-
sulin and HOMA-IR also significantly decreased after 
antiviral treatment, whereas the BMI value was not 
significantly affected. For the nonresponders (n=6), no 
significant changes were evident in BMI, fasting plas-
ma glucose, fasting serum insulin, and HOMA-IR at 6 
months after the end of antiviral treatment. Logistic 
regression analysis indicated that the only in-
dependent factor contributing to the reduction of in-
sulin resistance was the complete disappearance of 
HCV RNA at 6 months after the end of antiviral treat-
ment (SVR). Conclusions:  The clearance of HCV by 
the combination therapy of pegylated interferon α-2a 
and ribavirin improves insulin resistance by reducing 
fasting serum insulin and glucose levels. (Gut and 
Liver 2009;3:108-115)
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INTRODUCTION
  Chronic hepatitis C virus (HCV) infection is associated 
with a greater risk for the development of insulin 
resistance.
1 Greater insulin resistance is more prevalent 
among patients with HCV infection compared with those 
with other liver diseases and with the general popula-
tion.
2 In patients with HCV infection, insulin resistance is 
involved in progression of hepatic fibrosis,
3 the develop-
ment of hepatocellular carcinoma,
4,5 extrahepatic manifes-
tations,
6 and prognosis.
7 Thus, insulin resistance plays a 
crucial role in patients with HCV infection.
  The relationship between the severity of insulin resist-
ance and the HCV replicative level has not been cleared 
delineated. A recent work seems to suggest the possible 
relationship,
8 but it is still not clear whether HCV repli-
cation directly increases insulin resistance, or whether hy-
perinsulinemia stimulates viral replication, as suggested 
by in vitro data.
9 T h is  l a c k  o f  c o r r e l a t i o n  m a y  b e  d u e  t o 
the fact that the global level of insulin resistance might  
depend on the contribution from the adipose tissue and 
the muscle, two extrahepatic compartments that are not 
infected by HCV.
    The investigation considering the effect of antiviral 
therapy is another classical way to prove or disprove an 
association between infection and pathology. Romero- 
Gómez  et al.
10 have shown that insulin sensitivity might 
improve in patients who achieve HCV RNA clearance, 
while it did not improve in non-responders, despite the 
decrease in body mass index (BMI). An improved glucose Kim HJ, et al: HCV Clearance and Insulin Resistance   109
tolerance has been reported to follow successful antiviral 
treatment in at least two other studies.
11,12 However, fur-
ther, independent confirmation of these observations 
might be useful, especially, for the patients with chronic 
HCV infection who received pegylated interferon plus rib-
avirin combination treatment. The ability of this antiviral 
treatment to improve glucose metabolism would support 
the notion that HCV causes insulin resistance in patients 
with HCV infection. Accordingly, we studied the effects 
of clearance of HCV by combination treatment of pegy-
lated interferon plus ribavirin on insulin resistance.
MATERIALS AND METHODS
1. Subjects
  This was a prospective cohort study analyzing 28 pa-
tients with HCV infection who underwent the combina-
tion treatment of 180μg of pegylated interferon α-2a 
(Pegasys
Ⓡ, Roche, Seoul, Korea) and ribavirin (800-1,000 
mg per day, according to the genotype of HCV) at our in-
stitution from May 2004 to November 2006. The diag-
nosis was based on elevated serum aminotransferase lev-
el, histological examination, consistent detection of an-
ti-HCV and HCV-RNA. Patients who coincided with other 
causes of liver disease such as chronic hepatitis B, auto-
immune hepatitis, or alcoholic liver disease (greater than 
80 g alcohol per day for at least 1-month duration prior 
to the onset of illness) were excluded, as were those who 
had been taking corticosteroids or those with a history of, 
or evidence of, pancreatitis or pancreatic tumor. Clinical 
data was collected before antiviral treatment included age, 
sex, and alcohol consumption. BMI was calculated as 
body weight in kilograms divided by the square of height 
in meter (kg/m
2). Informed consent for participation in 
the study was obtained from each subject. The study pro-
tocol conformed to the ethical guidelines of 1975 
Declaration of Helsinki.
2. Laboratory determination
  Venous blood samples were taken in the morning after 
12-h overnight fast. Plasma glucose, serum alanine ami-
notransferase, aspartate aminotransferase, albumin, and 
total bilirubin levels were measured by using standard 
clinical methods (Department of Clinical Laboratory, 
Kangbuk Samsung Hospital, Seoul, Korea). Serum insulin 
levels were measured by electrochemi-luminescence im-
munoassay by using an autoanalyzer (Elecsys 1010/2010; 
Elecsys Modular Analytics E170; Roche, Basil, Switzer-
land). Serum C-peptide levels were measured by a com-
mercially available kit (Immulite, Diagnostic Products, 
Los Angeles, CA, USA). All patients had positive anti- 
HCVAb, as measured by EIA3 (Abbott Laboratories, 
Chicago, IL, USA). HCV-RNA was measured by Amplicor- 
HCV-Monitor 1.0 (Roche Diagnostics GmbH, Mannheim, 
Germany) at 12 weeks after the initiation of antiviral 
treatment, at the end of antiviral treatment and 6 months 
after the end of antiviral treatment. HCV genotype was 
determined by polymerase chain reaction with type-specif-
ic primers and genotypes were classified according to 
Simmonds’s classification system.
13
  Insulin resistance (IR) is defined as the condition in 
which normal amounts of insulin are inadequate to pro-
duce a normal insulin response from fat, muscle and liver 
cells. The most common type of insulin resistance is as-
sociated with a disease state known as metabolic 
syndrome. IR can progress to full type 2 diabetes. Insulin 
resistance was calculated on the basis of fasting levels of 
plasma glucose and serum insulin, according to the ho-
meostasis model assessment (HOMA) method. The for-
mula for the HOMA model is as follows: insulin resist-
ance (HOMA-IR) = fasting glucose (mg/dL) × fasting in-
sulin (μIU/mL)/405.
3. Treatment and follow-up
  All patients were treated with 180μg of pegylated in-
terferon  α-2a (Pegasys
Ⓡ,  R o c h e ,  S e o u l ,  K o r e a )  b y  s u b -
cutaneous injection once a week plus ribavirin (Viramid
Ⓡ, 
Ilsung Pharmaceuticals Co., Ltd., Seoul, Korea, 800 mg/ 
day for HCV genotype 2a and 1,000 mg/day for HCV 
genotype 1b) for either 6 months (for genotype 2a) or 1 
year (for genotype 1b). Patients were followed up until 6 
months after the conclusion of antiviral treatment and 
classified into two groups: sustained responder (n=22), 
who had undetectable HCV-RNA by Amplicor-HCV- 
Monitor 1.0 at 6 months after the conclusion of antiviral 
treatment; nonresponder (n=6) who had detectable 
HCV-RNA by Amplicor-HCV-Monitor 1.0 at 6 months af-
ter the conclusion of antiviral treatment.
4. Statistical analysis
  All data are expressed as mean±SD (standard devia-
tion). The Wilcoxon signed rank test was employed for 
analysis of paired samples. Statistical comparisons be-
tween the patients group were performed by Mann- 
Whitney U test for continuous variables and Fisher’s ex-
act test for categorical variables. Statistical correlation be-
tween HCV-RNA level and HOMA-IR was performed by 
Spearman’s correlation. A multivariate logistic regression 
model was used to determine the independent factors as-
s o c i a t e d  w i t h  t h e  d e l t a  H O M A - I R  v a l u e .  D a t a  w e r e  a n a -
lyzed using SPSS package (SPSS 11.5 version, SPSS Inc., 
Chicago, IL, USA). p values less than 0.05 were consid-110   Gut and Liver, Vol. 3, No. 2, June 2009
Table 1. Characteristics of the Patients
Sustained Nonres-
p-value
responder ponder
N 22  6 
Age (mean±SD, years)  57.6±8.9  50.8±9.6  NS
Male gender (%)  10 (45.5)  4 (66.7)  NS
BMI 24.1±3.7  22.4±2.4  NS
Presence of DM (%)   5 (22.7)  1 (16.7)  NS
Alanine aminotransferase   94.0±90.6  86.5±75.1  NS
 (IU/L)
Aspartate aminotransferase  86.6±56.8   84.8±44.1  NS
 (IU/L) 
Total bilirubin (mg/dL)   0.89±0.33   0.71±0.31  NS
Total cholesterol (mg/dL)  153.5±30.7  164.2±26.2  NS
Triglyceride (mg/dL)  134.5±60.2  162.3±71.7  NS
Higher HOMA-IR (≥3, %) 14 (63.6)  4 (66.7) NS
HCV genotype (1b/2a)  9/13  6/0  0.018
Viral load (log10 copies/mL)  5.50±0.90   6.34±0.54 0.022
24 h urine c-peptide (μg) 112.7±55.1 125.6±50.9  NS
Insulin (μIU/mL)   18.13±14.24  12.50±3.16 NS
C-peptide (ng/mL)   3.89±1.82   4.28±1.15  NS
Fasting plasma glucose 112.6±33.0  105.5±15.2 NS
 (mg/dL) 
HOMA-IR   5.28±4.55   3.34±1.24 NS
N, number; SD, standard deviation; NS, not significant; BMI, 
body mass index; DM, diabetes mellitus; HCV, hepatitis C 
virus; HOMA-IR, homeostasis model assessment-insulin 
resistance.
Fig. 1. Correlation between insulin resistance (HOMA-IR) and 
the status of viral replication (HCV RNA) before antiviral 
treatment.
Table 2. Comparisons of BMI, Fasting Plasma Glucose, Serum 
Insulin, C-peptide and HOMA-IR Levels between the Patients 
Group Infected with Genotype 1 and 2 HCV
Genotype Genotype  
p-value
12
 N  15 13
 BMI  23.6±3.4   23.9±3.8 NS
 Fasting plasma glucose  113.1±29.3 108.9±31.9   NS
  (mg/dL)
 Insulin (μIU/mL) 16.70±14.41 17.18±11.36 NS
 C-peptide (ng/mL)  4.47±1.77  3.98±1.85  NS
 HOMA-IR  4.86±4.54 4.86±3.79  NS
HCV, hepatitis C virus; N, number; SD, standard deviation; 
NS, not significant; BMI, body mass index; HOMA-IR, 
homeostasis model assessment-insulin resistance.
ered significant.
RESULTS
1. Characteristics of patients
  Baseline characteristics of the patients are summarized 
in Table 1. There was no significant difference in age, 
gender distribution, BMI, presence or absence of DM, the 
levels of serum aminotransferases, total bilirubin, total 
cholesterol, triglyceride, fasting plasma glucose, insulin, 
c-peptide and HOMA-IR between patients group of sus-
tained responder and nonresponder. In our study, the rate 
of sustained virologic response (SVR) in patients with 
higher HOMA-IR (＞3) was not significantly different 
from that of patients with lower HOMA-IR (≤3) (14/18 
[77.8%] for higher HOMA-IR group vs. 8/10 [80.0%] for 
lower HOMA-IR group, p＞0.05). HCV viral load de-
termined before the initiation of antiviral treatment 
(expressed as log10 copies/mL) was significantly higher in 
nonresponder group compared with that of responder 
group (p=0.022). In nonresponder group, the infection 
rate of genotype 1b (100%) was significantly higher than 
that of responder group (40.9%) by Fisher’s exact test 
(p=0.018). There was no significant correlation between 
the insulin resistance (HOMA-IR) and the status of viral 
replication (HCV-RNA) before the initiation of antiviral 
treatment (Fig. 1).
2. Changes in BMI, fasting plasma glucose, in-
sulin, c-peptide and HOMA-IR after antiviral 
treatment
  Changes in BMI, fasting plasma glucose, insulin and 
HOMA-IR, classified with the presence or absence of SVR 
after antiviral treatment are summarized in Fig. 2. For 
sustained responders (n=22), fasting plasma glucose level 
significantly decreased to 99.9±14.9 mg/dL from 112.6± 
33.0 mg/dL (p=0.035 by Wilcoxon signed rank test) at 6 
months after the end of antiviral treatment. Especially, 
fasting serum insulin and HOMA-IR significantly de-
creased to 10.40±3.12μIU/mL (p＜0.01 by Wilcoxon 
signed rank test) and 2.62±1.07 (p＜0.01 by Wilcoxon 
signed rank test) from 18.13±14.24μIU/mL and 5.28± Kim HJ, et al: HCV Clearance and Insulin Resistance   111
Fig. 2. BMI, fasting plasma glu-
cose, fasting serum insulin, and 
HOMA-IR before and after 
antiviral treatment in sustained 
responders (A, n=22) and non-
responders (B, n=6). Data were 
obtained before and at 6 months 
after the end of antiviral treat-
ment. Bar and vertical line is 
mean and SD value, respectively. 
*p＜0.05, 
†
p＜0.01.
BMI, body mass index; NS, not 
significant.
4.55 at 6 months after the end of antiviral treatment, 
respectively. However, there was no significant change in 
BMI value at 6 months after the end of antiviral treat-
ment compared with that before antiviral treatment (from 
23.8±3.5 to 23.7±3.5 kg/m
2, p=0.087). For non-
responders (n=6), no significant differences were seen in 
BMI (from 22.4±2.4 to 22.4±2.4 kg/m
2, p=0.564), fast-
ing plasma glucose (from 105.5±15.2 to 107.0±14.6 
mg/dL, p=0.833), fasting serum insulin (from 12.50± 
3.15 to 13.06±4.02μIU/mL, p=0.345) and HOMA-IR 
(from 3.34±1.24 to 3.45±1.28, p=0.500) at 6 months af-
ter the end of antiviral treatment compared with those 
before antiviral treatment.
  No significant differences of BMI, fasting plasma glu-
cose, serum insulin, serum c-peptide and HOMA-IR were 
noticed between the patients group of genotype 1 and 2 
HCV infection (Table 2). Changes in BMI, fasting plasma 
glucose, insulin and HOMA-IR, classified by the genotype 
of HCV after antiviral treatment are summarized in Fig. 
3. The levels of BMI were not significantly altered after 112   Gut and Liver, Vol. 3, No. 2, June 2009
Fig. 3. BMI, fasting plasma 
glucose, fasting serum insulin, 
and HOMA-IR before and after 
antiviral treatment in patients 
with genotype 1 HCV infection 
(A, n=15) and genotype 2 HCV 
infection (B, n=13). Data were 
obtained before and at 6 months 
after the end of antiviral treat-
ment. Data are mean and SD 
values. 
*p＜0.05, 
†
p＜0.01.
BMI, body mass index; NS, not 
significant.
antiviral treatment compared with those before antiviral 
treatment in patients with both the genotype 1 and 2 
HCV infection (for genotype 1, 23.6±3.4 to 23.5±3.2, 
p=0.184 by Wilcoxon signed rank test: for genotype 2, 
23.9±3.8 to 24.0±3.8, p=0.833 by Wilcoxon signed rank 
test). Fasting plasma glucose levels were not significantly 
altered at 6 months after the end of antiviral treatment 
compared with those before the treatment for patients 
with both the genotype 1 and 2 HCV infection (for geno-
type 1, 113.1±29.3 mg/dL to 101.4±10.5 mg/dL, p=0.280 
by Wilcoxon signed rank test: for genotype 2, 108.9±31.9 
mg/dL to 101.5±19.2 mg/dL, p=0.184 by Wilcoxon sign-
ed rank test). For both patients with genotype 1 and 2 
HCV infection, fasting serum insulin significantly de-
creased at the 6 months after the end of antiviral treat-
ment (for genotype 1, 16.70±14.41μIU/mL to 11.02± 
3.61μIU /m L, p= 0.047 by W ilcoxon signed rank test; for 
genotype 2, 17.18±11.36 μIU/mL to 10.92±3.37μIU/ 
mL, p=0.003 by Wilcoxon signed rank test). In addition 
the values of HOMA-IR significantly decreased at 6 Kim HJ, et al: HCV Clearance and Insulin Resistance   113
Table 3. Multivariate Logistic Regression Analyses for the Independent Contributing Factors to the Minus (Decreasing) Delta 
HOMA-IR Group
Variables  Category  Odds ratio  95% confidence interval  p-value
SVR Yes  50.0  3.74-668.35  0.003
Age Each 1 year decrease 1.07  0.91-1.15 0.091
Gender Male 5.86 0.16-217.98  0.338
ALT normalization Yes 15.95 0.23-1,128.90 0.203
HCV genotype 1b 0.23 0.01-8.41 0.425
T. bilirubin normalization Yes 7.8 0.15-333.33 0.305
SVR, sustained virologic response; ALT, alanine aminotransferase; T. bilirubin, total bilirubin.
months after the end of antiviral treatment for both pa-
tients with genotype 1 and 2 HCV infection (for genotype 
1, 4.86±4.54 to 2.79±1.10, p=0.018 by Wilcoxon signed 
rank test; for genotype 2, 4.86±3.79 to 2.81±1.25, 
p=0.003 by Wilcoxon signed rank test).
  We have categorized the patients group into the minus 
(decreasing) delta HOMA-IR group and plus (increasing) 
delta HOMA-IR group, respectively. We than performed 
multivariate logistic regression analysis for the indepen-
dent contributing factors to the minus (decreasing) del-
ta-HOMA-IR group, and identified that SVR (complete 
disappearance of HCV RNA at 6 months after the end of 
antiviral treatment) was the only independent con-
tributing factor to minus (decreasing) delta-HOMA-IR 
group (Table 3).
DISCUSSION
  The present study demonstrated that clearance of HCV 
by combination treatment of pegylated interferon α-2a 
plus ribavirin improved HOMA-IR due to the decrease in 
fasting serum insulin and plasma glucose level. These 
findings indicate that HCV itself might be involved in the 
development of insulin resistance.
    Insulin resistance can be caused by many factors. 
Obesity is a common factor for the development of in-
sulin resistance.
14 Although, greater insulin resistance was 
noticed in our study patients, mean values of BMI were 
within normal limit at the enrollment and no significant 
change of BMI was noticed after the antiviral treatment.
  In an epidemiologic study, Bahtiyar et al.
15 reported that 
obesity was not associated with the development of in-
sulin resistance in patients with HCV infection. In addi-
tion, the development of insulin resistance was noticed by 
1 month of age in the absence of either overt liver injury 
or excessive body weight gain in HCV core transgenic 
mice
16 and serum HCV core protein levels were asso-
ciated with HOMA-IR values in patients with chronic 
hepatitis C.
17 Moreover, a significant increase in the in-
cidence of diabetes was seen in subjects with higher titers 
of HCV core compared with subjects with low titers of 
H C V  c o r e  o r  a n t i - H C V  n e g a t i v e  s u b j e c t s  a t  t h e  p o p -
ulation level during 7 years of follow-up.
18 Taken togeth-
er, these findings suggest that HCV itself may cause in-
sulin resistance.
  In our study, insulin resistance (HOMA-IR) was im-
proved only in sustained responder group who had un-
detectable HCV-RNA at 6 months after the end of anti-
viral treatment and insulin resistance was not improved 
in nonresponder group who had not achieved HCV clear-
ance at 6 months after the end of antiviral treatment. 
These results of our study might add another piece of a 
puzzle for the causal relationship of HCV itself to insulin 
resistance. However, there are some difficulties in estab-
lishing a definite relationship between HCV infection and 
diabetes on the basis of our results only. Practically, there 
are other numerous factors in patients, perturbing the 
verification of the definite relationship, such as advanced 
liver injuries, obesity and aging. Additionally, before the 
initiation of antiviral treatment, significant correlation be-
tween the status of HCV replication and insulin resist-
ance was not noticed in patients group of our study (Fig. 
1). However, previous study
16 showed that the HCV core 
gene transgenic mice exhibited insulin resistance as early 
as 1-month old, despite an apparent absence of glucose 
intolerance. Furthermore, development of insulin resist-
ance without any liver injury or excessive body weight 
gain, clearly indicates that infection of HCV per se is a 
cause of the development of insulin resistance. Additio-
nally, multivariate logistic regression analysis performed 
in our study showed that only SVR (complete complete 
disappearance of HCV RNA at 6 months after the end of 
antiviral treatment) was the independent contributing fac-
tor to the minus (decreasing) delta HOMA-IR group and 
other clinical parameters, such as age, gender, HCV geno-
type, the temporal change of BMI, and ALT (indicator of 
liver inflammation) were not significant contributing fac-
tors to minus (decreasing) delta HOMA-IR group. These 114   Gut and Liver, Vol. 3, No. 2, June 2009
contradictory findings of previous and our studies suggest 
that it is still not clear whether HCV replication itself di-
rectly increases insulin resistance. We speculated that 
mechanisms other than replication numbers of HCV, such 
as various pathologic changes induced by HCV infection 
might influence the development of insulin resistance.
  Interferon induces insulin resistance immediately after 
administration in healthy controls.
19 In chronic hepatitis 
C patients treated for 2 weeks, interferon induces a de-
crease in glucose uptake by peripheral tissue and the 
liver.
20 However, this effect disappears when analyzed af-
ter 3 months of treatment
21 or during the follow up at 
the end of treatment.
22 In our study, the clearance of the 
HCV induced an improvement in insulin resistance, de-
spite a potential increase in insulin resistance associated 
with the interferon treatment. Even in nonresponders, in-
terferon did not worsen insulin resistance and these data 
also support a link between active HCV replication and 
insulin resistance.
  Previous study by Romero-Gómez et al.
10 has shown 
that insulin resistance strongly influences the rate of SVR 
in patients infected by genotype 1. However, in our study, 
the rate of SVR in patients with higher HOMA-IR (＞3) 
was not significantly different from that of patients with 
lower HOMA-IR (≤3). This finding could be attributed 
to the relatively small number of nonresponders (n=6) 
included in our study.
  Previous report
23 has shown that HCV genotype 1 and 
4 are independently associated with increased HOMA-IR 
and insulin resistance. Another report
24 has shown that 
HCV genotype 3 has a negative independent association 
with insulin resistance. In our study, no significant differ-
ences of BMI, fasting plasma glucose, serum insulin and 
HOMA-IR levels were noticed between the patients group 
infected with genotype 1 and 2 HCV (Table 2). To our 
best knowledge, our study is the first report comparing 
the genotype 1 and 2 HCV infection for the association 
with several metabolic parameters, such as BMI, fasting 
plasma glucose level, serum insulin and c-peptide, and in-
sulin resistance. However, further comparisons among the 
variable genotypes of HCV more than genotype 1 and 2 
(such as HCV genotype 3 and 4) will delineate the true 
impact of each HCV genotype on the metabolic para-
meters. Significant reduction of insulin and HOMA-IR 
were noticed in both patients group of genotype 1 and 2 
HCV infection at 6 months after the end of antiviral 
treatment (Fig. 3). In contrast, fasting plasma glucose lev-
el was not significantly changed in both HCV genotype 1 
and 2 patients group at 6 months after the end of anti-
viral treatment. However, in sustained responders, sig-
nificant reduction of fasting plasma glucose level was no-
ticed after the end of antiviral treatment, so the difference 
of the results of the temporal change of fasting plasma 
glucose level according to the presence or absence of SVR 
or HCV genotype might be attributed to the alteration of 
number of each patients group between the two statistical 
comparisons.
  The drawback of our study was insufficient number of 
enrolled patients, especially for the nonresponders, to elu-
cidate the causal relationship between the successful HCV 
eradication by the combination treatment of pegylated in-
terferon plus ribavirin and the improvement of insulin 
resistance.
  In conclusion, our study found that the clearance of 
HCV by the combination therapy of pegylated interferon 
α-2a and ribavirin improved insulin resistance by the re-
duction of fasting serum insulin and glucose level.
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